A promising pipeline of diverse molecular structures

Pipeline

QBiotics has identified significant unmet medical needs and market opportunities in a range of therapeutic areas.

Our current focus is on treating solid tumours and chronic wounds, with an additional early programme in antibiotics.

Our anticancer drug candidate, tigilanol tiglate, is an intratumoural, oncolytic small molecule with potential in the treatment of a wide range of solid tumours by intratumoural injection. Tigilanol tiglate is currently in clinical Phase II development for the treatment of soft tissue sarcomas within a clinical trial in the United States. The development programme has been awarded Orphan Drug Designation by the FDA for this indication. Additionally, a clinical trial in head and neck cancers is underway in both the United Kindom and Australia.

Our wound healing drug candidate, EBC-1013, is a topically applied, semi-synthetic small molecule, that has the potential for the treatment of a wide range of chronic and acute wounds and burns. EBC-1013 is currently enrolling patients in its clinical Phase I safety trial in patients with venous leg ulcers in Australia.

Underpinning QBiotics' current programmes is the Company's epoxytiglianes platform. Tigilanol tiglate and EBC-1013 are two of three interlinked programmes from this platform, with an antibiotic programme in lead selection stage.